Although past preclinical studies have shown that alectinib has a significant inhibitory effect on RET fusion genes (10, 95), but from the results of these clinical trials, alectinib is difficult to offer considerable disease control results in patients with advanced and chemotherapy-refractory RET fusion-positive NSCLC. This evidence concerns the gene RET and non-small cell lung carcinoma.